RA was well tolerated in the Phase I trial. Now MBX is planning a Phase II trial in post-bariatric hypoglycaemia patients.

A live webcast of the presentation will be available on the investor relations page of the Terns Pharmaceuticals website at https://ir.ternspharma.com. A replay of the webcasts will be archived on ...

This is the beginning of a revolution, and how you engage and how you attack it is going to really set the stage for your ...

Injectable GLP-1 agonists help people struggling to lose weight. Patients are finding the drug also helps reduce recurring ...

Recent market research reveals that glucagon-like peptide-1 (GLP-1) injections are set to dominate the obesity treatment ...

Hello, Health Rounds Readers! Today we feature a study that found yet another potential health benefit of GLP-1 drugs, this ...

To identify this year’s Drugs to Watch 2025 list, Clarivate drew from expertise from over 160 Clarivate analysts covering ...

Research indicates that GLP-1 diabetes drugs such as tirzepatide and semaglutide may reduce surgical complications in diabetic patients. Insulin proves superior to oral medication for managing ...

The study showed diabetic patients taking GLP-1 drugs, such as semaglutide and tirzepatide, faced significantly lower risks of 30-day readmission, wound re-opening and hematoma after surgery, compared ...

The biotech industry is booming thanks to the rising demand for personalized medicine, investment in innovations, and ongoing ...

The move intensifies an ongoing legal battle, as Novo Nordisk joins its major competitor Eli Lilly in opposing a recent initiative by the Outsourcing Facilities Association to include liraglutide in ...

The health benefits of time-restricted eating go beyond weight loss and may be most prominent in patients already with ...